The programme for the day is divided roughly into two sections: pharmacology in the morning and the clinicians in the afternoon. The topic will largely concern recent interest in dopaminergic mechanisms in schizophrenia and the role of dopaminergic mechanisms in particular in the actions of drugs used in the treatment of schizophrenia. My feeling is that dopaminergic mechanisms have more relevance to therapeutics than to etiology, and I would like to discuss that issue with you in a little more detail.
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The programme for the day is divided roughly into two sections: pharmacology in the morning and the clinicians in the afternoon. The topic will largely concern recent interest in dopaminergic mechanisms in schizophrenia and the role of dopaminergic mechanisms in particular in the actions of drugs used in the treatment of schizophrenia. My feeling is that dopaminergic mechanisms have more relevance to therapeutics than to etiology, and I would like to discuss that issue with you in a little more detail. Dopaminergic Mechanisms in Schizophrenia and their Relevance to Therapeutics and Aetiology by Dr L L Iversen (MRCNeurochemicalPharmacology Unit, Department ofPharmacology, Medical School, Hills Road, Cambridge)
The notion that schizophreniia might be associated with some abnormality of brain chemistry is not new and there have been numerous unsuccessful attempts to identify a hypothetical toxic metabolite. Recently, however, research attention has focused on an alternative appioach, which is based on our new knowledge of the mode of action of drugs used in the treatment of schizophrenia. Various lines of evidence have led to the conclusion that all of the drugs that have been found to be effective in the treatment of schizophrenic symptoms act by blocking receptors for the CNS transmitter dopamine. This evidence has been discussed in detail elsewhere and will be summarized only briefly here (Snyder 1973 , Snyder, Banerjee et al. 1974 , Crow et al. 1976 , Iversen 1977) .
Our knowledge of the distribution of dopamine as a neurotransmitter in various systems of neurones in the mammalian brain has advanced rapidly in recent years, thanks to the development of histochemical techniques that allow the visualization and mapping of such cells (Ungerstedt 1971 , Lindvall & Bjorklund 1974 . The dopamine neurones are arranged in two principal systems (Fig 1) one originating from cells in the substantia nigra and innervating various regions of neostriatum and a second originating from cells in the ventral tegmentum (the so-called AlO group) whose fibres project to various limbic structures, including nucleus accumbens, olfactory are not antagonized by a-or /3-adrenoceptor antagonist drugs. Amphetamine appears to elicit many of its behavioural effects indirectly by causing a release of endogenous dopamine in the brain, since selective lesions of CNS dopaminergic pathways abolish its behavioural effects (Creese & Iversen 1974 , Kelly et al. 1975 . This is an important conclusion, since amphetamine in large doses is capable of causing a schizophrenialike psychosis in man (Connell 1958 , Angrist et al. 1974 and produces an acute exacerbation in schizophrenic patients (Davis 1974 ). Furthermore, amphetamine psychosis is alleviated by drugs known to be effective in the treatment of schizophrenia. Such drugs also block the behavioural stimulant effects of amphetamine in animals and this is such a consistent property that this test has been used to predict new compounds likely to exhibit antipsychotic actions in man (Randrup & Munkvad 1974 , Janssen et al. 1967 .
The hypothesis that antipsychotic drugs (major tranquillizers, neuroleptics) of many different chemical classes share a common ability to block CNS dopamine receptors is supported by other lines of evidence. All such drugs cause a selective stimulation of the rate of synthesis and metabolism of dopamine in the animal brain, apparently as an adaptive response to dopamine receptor blockade (Carlsson & Lindqvist 1963 , Sedvall 1975 . Furthermore, antipsychotic drugs cause an increase in the rate of secretion of the anterior pituitary hormone prolactin both in animals and in man (Clemens et al. 1974 , Langer et al. 1977 . The secretion of prolactin appears to be under inhibitory control by dopamine and the receptors involved seem to have the same properties as those in CNS.
The most direct evidence for dopamineblocking properties in these drugs has come, however, from studies of CNS dopamine receptor mechanisms in vitro. These have been of two types. We and others have found that many antipsychotic drugs act as potent inhibitors of the ability of dopamine to stimulate cyclic AMP formation in homogenates of dopamine-rich areas of brain (Iversen 1975) . The actions of antipsychotic drugs on the dopamine stimulated adenylate cyclase are, however, anomalous, in that certain potent antipsychotic drugs (notably pimozide and the related butyrophenone series) are only weakly active on this test. A more recently developed test system depends on measurements of the saturable high affinity binding of the radioactively labelled butyrophenones, haloperidol or spiroperidol, to specific membrane sites in brain homogenates , Seeman et al. 1976 , Laduron & Leysen 1977 . Such sites occur only in dopamine-rich areas of brain, and appear to represent CNS dopamine receptors.
There is a good correlation between the rank order of potencies of various antipsychotic drugs in clinical use and their potencies in competing for the binding of labelled haloperidol or spiroperidol in vitro (Fig 2) . Creese et al. (1976) , for example, reported a correlation coefficient of 0.87 between average clinical dose and potency against labelled haloperidol binding for a series of 22 drugs and Seeman et al. (1976) described similar results and pointed out that the absolute concentrations of drugs needed to inhibit the binding of haloperidol were very similar to the free concentrations known to occur in plasma during drug treatment.
Although all of these approaches indicate that antipsychotic drugs act as dopamine blockers, some important differences in the results obtained Reproducedfrom Seeman et al. 1976, by kind permission) with the different biochemical test systems remain to be explained. It is possible that dopamine stimulated adenylate cyclase reflects the properties of a different type of CNS dopamine receptor from that studied in drug-binding experiments. Thus, it is possible that more than one type of CNS dopamine receptor exists, and that these different receptor types may have differential sensitivities to drugs. If the latter hypotheses proved to be correct, it would open a new avenue for the development of neuroleptic drugs which selectively affected one or other type of dopamine receptor. Another line of approach to the rational development of new drugs for the treatment of schizophrenia lies in the combination of dopamine-blocking activity with some other pharmacological activity in the same molecule. Thus, it has been proposed that the low incidence of Parkinsonian side-effects seen with some drugs (such as clozapine and thioridazine) may be related to the fact that these drugs combine dopamine-blocking and potent antimuscarinic actions (Miller & Hiley 1974 . A recent report suggests that the sedative properties of certain neuroleptics (notably thioridazine, chloropromazine, promazine and clozapine) is related to their potent a-adrenoceptor antagonist activities rather than to their dopamine-blocking properties (Peroutka et al. 1977) .
The dopamine hypothesis of the mode of action of antipsychotic drugs seems to be firmly established. Many unanswered questions remain, for example in defining the precise characteristics of CNS dopamine receptors and their possible subtypes. Another key question concerns the anatomical location of the dopamine receptors that are critical in determining the antipsychotic effect of these drugs. Of the many different regions of brain containing dopamine, it is generally thought likely that the crucial site lies in the mesolimbic and cortical dopamine projection areas, but there is little evidence to support this speculation.
Another area of debate concerns the implications of these findings for understanding the biochemical ietiology of schizophrenia. Because drugs used in treating the symptoms of the illness act by blocking CNS dopaminergic mechanisms, does this necessarily imply that such mechanisms are overactive or abnormally responsive in the schizophrenic brain? Clearly-it is a possibility, but it is not a necessary prediction from the available information. Thus, drugs with anticholinergic actions are effective in treating the symptoms of Parkinson's disease, but this does not mean that Parkinson's disease should be viewed as a cholinergic hyperactivity state. Similarly in schizophrenia, it may prove that an abnormality exists in some chemical system quite distinct from the dopaminergic one, but impinging in some way upon, or in balance with, the dopaminergic system. A direct test of such hypotheses may be possible by biochemical measurements on post-mortem brain samples from patients dying with schizophrenia and this approach is currently being assessed in our laboratory.
